Co-Dx Executive Leadership
Meet the people bringing the Power to Know™ to the world
Dwight H. Egan, Chief Executive Officer
Mr. Dwight Egan has been an officer and director since April 2013. Mr. Egan has been engaged in the private investment business from February 1999 to the present. He was a senior executive at Data Broadcasting Corporation, a leading provider of wireless, real-time financial market data, news, and sophisticated fixed-income portfolio analytics to 27,000 individual and professional investors from 1995 to 1999. He co-founded and served as CEO and Chairman of the Board of Broadcast International, Inc. from 1984 to 1995 when Data Broadcasting Corporation acquired Broadcast International and created CBS MarketWatch, a leading financial news site, and participated in its initial public offering. Mr. Egan’s prior experience in directing a public company and working with capital markets gives him valuable experience in advising the board on matters of finance and operations.
Brian L. Brown, CPA, Chief Financial Officer
Mr. Brian L. Brown was appointed Chief Financial Officer in February 2021. Previously, he served as Chief Financial Officer of A-Core Concrete Cutting, Inc., a privately held specialty construction company, and was Vice President of Accounting, Treasury & Investor Relations, in addition to Director of Finance, for Sportsman’s Warehouse Holdings, Inc. (Nasdaq: SPWH), a publicly traded outdoor sporting goods retailer. Prior to becoming a Certified Public Accountant in 2007, Mr. Brown received his Master of Professional Accountancy (MPrA) degree from the University of Utah David Eccles School of Business in 2001 and a Bachelor of Arts Degree in Accounting from the University of Utah in 2000. Mr. Brown’s experience in finance, accounting, and roles directing successful financial departments all help make Mr. Brown a critical component of the Co-Diagnostics leadership team.
Mark Poritz, Ph.D., Chief Scientific Officer
Dr. Mark Poritz was appointed Chief Scientific Officer in November 2022. Previously, he served as CSO of the Co-Diagnostics subsidiary, Idaho Molecular, where he was supervising the development of the biochemical reagents for the Co-Dx PCR platform. Dr. Poritz has spent the last 25 years working on infectious disease therapeutics and diagnostics. He joined Idaho Technology in 2002 to write the NIH grant that funded the initial development of the FilmArray IVD platform. He led the development of the chemistry and molecular biology aspects of the first FilmArray product – the respiratory pathogen panel. After the acquisition of Idaho Technology/BioFire by bioMérieux, Dr. Poritz moved to BioFire Defense where he led the assay design effort for the US Department of Defense FilmArray Global Fever panel. Dr. Poritz received his undergraduate degree from Harvard College and his PhD in Genetics from the University of California at San Francisco.
Ivory Chang, Chief Regulatory Affairs Officer
Ms. Chang was appointed Chief Regulatory Affairs in August 2023. Previously, she served as Sr. Director of Regulatory Affairs and Clinical Affairs at Thermo Fisher Scientific, where she led the global registration strategy, including the US FDA for the various PCR and sequencing platforms. Ms. Chang has spent 16 years working on infectious disease and cancer diagnostics. Lately, Ms. Chang has been actively involved in new AI/ML software regulations and led BARDA program for Danaher’s new diagnostic platform in 2020. Ms. Chang also led regulatory development and strategies for RUO reagents, instruments, and LDT as Regulatory Director at Agilent Technology and Genomic Health. Prior to specializing in IVD regulations, Ms. Chang acquired many years of 510k and PMA submission experience for traditional cardiovascular medical devices. Ms. Chang’s expertise in in vitro diagnostics (IVD) and medical device regulations is critical in navigating the complex global regulatory environment for Co-Diagnostics’ current and future product roadmap in the endemic era.
Ms. Chang received her undergraduate degree in Microbiology from Taiwan and her postgraduate degree in Advanced Instrumentation Systems from University College London (UCL) in England, UK.
Mayuranki Almaula, Ph.D., Sr. VP Overseas Operations and Strategic Alliances
Dr. Mayuranki Almaula is responsible for establishing clinical verification and validation strategies that support our diagnostic portfolios. This involves supporting the India-based clinical and manufacturing operations for our joint venture, CoSara Diagnostics Pvt Ltd. Dr. Almaula has provided support in establishing relationships across multiple continents for companies including Insilico Sciences, as Business Development Director, Gen Probe (now Hologic), as supporting the Senior Executive VP of Business Development in defining and executing their India strategy, and Symbiosis Biowares in their International Business Development strategy. Mayuranki completed a Master’s in Microbiology from Maharaja Sayajirao University Baroda and a doctorate in Microbiology from Stanford University.